Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
POAI

POAI - Predictive Oncology Inc Stock Price, Fair Value and News

$5.04+0.14 (+2.86%)
Market Closed

Price Targets

Target 1Y

$5.14

Target 3M

$5.79

Target 6M

$5.47

POAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

POAI Price Action

Last 7 days

-14.3%

Last 30 days

-8.9%

Last 90 days

-31.2%

Trailing 12 Months

-74.3%

POAI RSI Chart

POAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

POAI Valuation

Market Cap

17.1M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

136.39

EV/EBITDA

-0.84

Price/Free Cashflow

-2.14

POAI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.14

Target 3M

$5.79

Target 6M

$5.47

POAI Fundamentals

POAI Revenue

Revenue (TTM)

125.4K

Rev. Growth (Yr)

-7.4%

Rev. Growth (Qtr)

34.9%

POAI Earnings

Earnings (TTM)

-84.3M

Earnings Growth (Yr)

-2.4K%

Earnings Growth (Qtr)

-3.7K%

POAI Profitability

EBT Margin

-30346.69%

Return on Equity

108.92%

Return on Assets

-2.7K%

Free Cashflow Yield

-46.74%

POAI Investor Care

Shares Dilution (1Y)

663.50%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025190.3K125.7K125.4K0
2024390.6K288.7K186.8K84.8K
20231.4M1.5M1.8M492.6K
20221.5M1.5M1.6M1.5M
20211.2M1.4M1.2M1.4M
20201.5M1.3M1.3M1.3M
20191.3M1.2M1.4M1.4M
2018891.3K1.1M1.3M1.4M
2017534.8K556.2K574.1K654.8K
2016600.0K451.4K500.2K456.5K
20151.0M948.3K636.9K654.4K
2014399.1K566.5K855.9K951.6K
2013317.0K442.9K499.1K479.7K
2012119.3K141.9K173.2K188.8K
2011042.7K69.7K96.6K
200900015.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Predictive Oncology Inc

POAI
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.
 CEO
 WEBSITEpredictive-oncology.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES31

Predictive Oncology Inc Frequently Asked Questions

POAI is the stock ticker symbol of Predictive Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Predictive Oncology Inc is 17.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check POAI's fair value in chart for subscribers.

The fair value guage provides a quick view whether POAI is over valued or under valued. Whether Predictive Oncology Inc is cheap or expensive depends on the assumptions which impact Predictive Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for POAI.

As of Tue Jan 27 2026, POAI's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 136.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. POAI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Predictive Oncology Inc has provided -0.655 (multiply by 100 for percentage) rate of return.